[A case of maxillary sinus carcinoma showing long time survival after lung metastasis with administration of S-1 as tumor dormancy therapy].
The patient is a 65-year-old man, who underwent curative resection for maxillary sinus carcinoma after chemoradiation. Lung metastases were observed two months following resection, and were treated with S-1 at a dose of 120 mg/day. One course of the S-1 administration regimen consisted of 2 weeks and a 1-week interval. The patient achieved long survival for 527 days with no adverse reaction. Therefore, this treatment on an outpatient basis greatly contributed to his quality of life. We consider S-1 as a first-line anti-cancer drug for tumor dormancy therapy.
Satoh
Akira
A
Oral Diagnosis and Medicine, Dept.of Oral Pathobiological Science, Hokkaido University Graduate School of Dental Medicine.
Satoh
Takehiko
T
Kaneta
Hiroyuki
H
Kato
Takumi
T
Notani
Ken-Ichi
K
Kitagawa
Yoshimasa
Y
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008444:Maxillary Sinus Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D010094:Oxonic Acid / Q000627:therapeutic use*; D017741:Survivors; D005641:Tegafur / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid